LOGIN
Oral administration of salmon calcitonin for postmenopausal women with low bone mass
December 2016
Oral administration of salmon calcitonin for postmenopausal women with low bone mass
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
Efficacy and safety of oral recombinant calcitonin tablets in postmenopausal women with low bone mass and increased fracture risk: a randomized, placebo-controlled trial
Osteoporos Int. 2014 Nov;25(11):2649-56Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
129 postmenopausal women with low bone mass were randomly assigned to receive either salmon calcitonin orally or placebo once daily for 1 year. The outcomes of interest were the change in bone mineral density (at the lumbar spine, femoral neck, trochanter, and total hip) and collagen type 1 C-telopeptide (CTx-1). The findings demonstrated a significant increase in lumbar spine bone mineral density...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.